Portal de Periódicos da CAPES

EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer

2017; Impact Journals LLC; Volume: 8; Issue: 43 Linguagem: Inglês

10.18632/oncotarget.20095

1949-2553

Xueli Nan, Chao Xie, Xueyan Yu, Jie Liu,

Quinazolinone synthesis and applications

// Xueli Nan 1, 2 , Chao Xie 2 , Xueyan Yu 3 and Jie Liu 2, 4 1 School of Medicine and Life Sciences, University of Ji’nan-Shandong Academy of Medical Sciences, Shandong, China 2 Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong, China 3 Department of Oncology, Shandong Provincial Chest Hospital, Shandong, China 4 Shandong Academy of Medical Sciences, Shandong, China Correspondence to: Jie Liu, email: lj1260814@126.com Keywords: EGFR TKI, first-line treatment, non-small-cell-lung cancer, EGFR mutations, combined therapy Received: February 21, 2017 Accepted: July 26, 2017 Published: August 09, 2017 ABSTRACT After the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs) have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A series of studies have shown that EGFR TKI monotherapy as first-line treatment can benefit NSCLC patients harbouring EGFR mutations. Besides, combination strategies based on EGFR TKIs in the first line treatment have also been proved to delay the occurrence of resistance. In this review, we summarize the scientific literature and evidence of EGFR TKIs as first-line therapy from the first-generation EGFR TKIs to conceptually proposed fourth-generation EGFR TKI, and also recommend the application of monotherapy and combination therapies of the EGFR-based targeted therapy with other agents such as chemotherapy, anti-angiogenic drugs and immunecheckpoint inhibitors.